Back to results
US 2017/0253662 A1Published application
Dosage and administration of anti-egfr therapeutics
AssigneeMerrimack Pharmaceuticals, Inc.
InventorsJeffrey David KEARNS, Beni B. WOLF
Life of this patent
Estimating the term…
Abstract
Methods for optimizing a therapeutic response in a patient (e.g., a cancer patient) to an anti-EGFR therapy, and methods for preventing or ameliorating infusion reactions in a patient receiving an anti-EGFR therapy are disclosed.
Claims25
A method of administering a mixture of two or more monoclonal anti-EGFR antibodies to a human cancer patient,
- the method comprising initially administering the mixture to the patient as a first and a second intravenous infusion during an initial two week treatment cycle, comprising a first week and a second week, wherein:
- i. a first dose of the mixture of anti-EGFR antibodies is administered during the first week at a rate of X mg/hour for a first ½ hour, immediately followed by a rate of 2X mg/hour for a second ½ hour, immediately followed by a rate of 4X mg/hour until all of the first dose has been administered;
- and
- ii. a second dose of the mixture of anti-EGFR antibodies is administered during the second week at a rate of X mg/hour for a first ½ hour, immediately followed by a rate of 2X mg/hour for a second ½ hour, immediately followed by a rate of 4X mg/hour for a third ½ hour, immediately followed by a rate of 8X mg/hour until all of the second dose has been administered.
1 more element
A method of administering a mixture of two or more monoclonal anti-EGFR antibodies to a human cancer patient,
- the method comprising initially administering the mixture to the patient as a first and a second intravenous infusion over a two week cycle as priming doses in sequence as set forth in the following table:
- Infusion
- Mixture
- Cumulative
- Rate
- Infusion Rate
- Infused
- Mixture
- Infusion
- Sequence1
- (mg/hr)
- (mg)
- Infused (mg)
- 1st Infusion
- 1st Rate
- 25
- 12.5
- 12.5
- (Priming Week 1)
- 2nd Rate
- 50
- 25.0
- 37.5
- 3rd Rate
- 100
- 187.5
- 225.0
- 2nd Infusion
- 1st Rate
- 25
- 12.5
- 12.5
- (Priming Week 2)
- 2nd Rate
- 50
- 25.0
- 37.5
- 3rd Rate
- 100
- 50.0
- 87.5
- 4th Rate
- 200
- 362.5
- 450
- 1per infusion
- wherein the 1st infusion of the mixture is administered during the priming week 1 at the 1st rate for a ½ hour, immediately followed by the 2nd rate for a second ½ hour, immediately followed by the 3rd rate until all of the first dose and 225 mg of mixture has been administered;
- wherein the 2nd infusion of the mixture is administered during priming week 2 at the 1st rate for a ½ hour, immediately followed by the 2nd rate for the second ½ hour, immediately followed by the 3rd rate for a ½ hour, immediately followed by the 4th rate until all of the first dose and 450 mg of mixture has been administered;
- and
- wherein the mixture of monoclonal IgG1 anti-EGFR antibodies is administered to a human cancer patient diagnosed with colorectal cancer.
47 more elements
Dependencies are inferred from the claim text.